Affectis Pharmaceuticals AG

Fraunhoferstrasse 13
82152 Martinsried
Germany

Contact

About Affectis Pharmaceuticals

Affectis Pharmaceuticals is a biopharmaceutical company focused on novel concepts for the treatment of psychiatric disorders and inflammatory diseases. The company discovers and develops drugs based on pioneering findings in the fields of depression, schizophrenia, and inflammation. Affectis was a spin-out from the Max-Planck Institute of Psychiatry in 2004, and since then has successfully advanced several compounds into the company’s development pipeline.

Read more about Affectis Pharmaceuticals

Facts about Affectis Pharmaceuticals Facts about Affectis Pharmaceuticals

Industry : Pharma

News about Affectis Pharmaceuticals

27-Jan-2012 | research and development

Affectis Granted Patent for AFC-5128, other P2X7 Antagonists

Affectis Pharmaceuticals AG announced that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which ...

Read news

10-Jun-2011 | business & finance

Affectis Pharmaceuticals and Merck Serono Announce an Agreement to Develop Oral Drugs for Neurodegenerative Diseases

Merck Serono to develop compounds from Affectis targeting P2X7 receptors

Read news

24-Mar-2010 | people

Affectis Pharmaceuticals Raises €3.3M in Financing and Names Alex Martin Chief Executive Officer

Affectis Pharmaceuticals AG announced it has raised €3.3M in the first tranche of a Series D financing. Existing investors LSP, Aescap Venture, KfW, ...

Read news

05-Mar-2007 | business & finance

Dalton Pharma Services and Affectis Pharmaceuticals of Germany enter into a Contract Services Agreement

Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider, announced the company has entered into a Contract Services Agreement ...

Read news

08-Feb-2005 | business & finance